オメガ3処方薬の市場規模、シェア、動向分析レポート：流通チャネル別（病院、オンライン薬局）、用途別（高トリグリセリド血症）、薬剤別（Vascepa、Lovaza）、地域別、セグメント別予測、2022年～2030年

オメガ3処方薬市場の成長と動向

Grand View Research, Inc.の新しいレポートによると、世界のオメガ3処方薬の市場規模は、予測期間中に8.27％のCAGRを記録し、2030年までに25億2000万米ドルに達すると予想されています。この産業の成長は、心血管疾患（CVD）の症例数の増加や食生活の変化に起因するものです。血中のトリグリセリドレベルの上昇は、現在、心血管疾患のリスク上昇と関連していることが知られています。2021年の欧州心臓病学会によると、毎年1790万人がCVDで死亡しており、世界の死因の第1位となっています。さらに、医薬品への製品応用の可能性が拡大しているため、業界関係者によるオメガ3ベースの医薬品の発売がその成長を後押しすると予想されます。

例えば、2020年、米国に拠点を置くアマリン社が製造するオメガ3系医薬品「VASCEPA」について、米国FDAは新たな心血管適応とラベル拡大を承認しました。中性脂肪が増加すると動脈が狭くなり、心筋梗塞や脳卒中のリスクが高まります。また、膵臓の炎症である膵炎も、極端に高い値から生じることがあります。トリグリセリドの値は、糖尿病や肥満の結果として上昇しますが、これは広く知られている問題です。アメリカの成人の平均25%は、血中アルコール濃度のボーダーラインが高いと言われています。オメガ3脂肪酸の薬は、米国FDAが承認した500mg/dl以上のトリグリセリド値に対してのみ処方されます。オメガ3処方薬はCOVID-19の大流行時に大きな市場の動きを示しました。

これは、CVD患者の管理における重要な役割に起因しています。例えば、2021年8月、Woodward Pharma Services LLCは、GlaxoSmithKlineからLOVAZAを買収したと発表しました。同社はさらに、消費者と医療提供者を教育し、同製品のより高い採用を促進することを目指しています。さらに、トリグリセリドの低下に関する複数の研究開発研究が行われており、トリグリセリドレベルの上昇に関する17の組織的無作為化臨床試験の結果を組み合わせて分析すると、処方されたオメガ3脂肪酸薬によってレベルが20～30%低下することが示唆されています。これは、高い製品需要を生み出すと予想されます。

オメガ3処方薬市場レポートハイライト

バセパはCVDのリスク低減を目的とした患者への使用がFDAに承認されているため、バセパ薬セグメントが2021年に最大の売上シェアを占めています。

用途別では、高トリグリセリド血症分野が予測期間中に最も速い成長率を記録すると予想されます。

この成長は、トリグリセリドレベルが上昇した患者に対するオメガ3処方薬の使用が増加していることに起因しています。

北米は、CVDが同地域の主要な死因であり、対象疾患の有病率が高いことから、2021年には世界の産業を支配していました。

主なプレイヤーは、需要の高まりに対応し、効率的な治療オプションを提供するために、既存の薬剤から高度で新規な剤形の開発に注力しています。

目次

第1章 オメガ3処方薬市場：調査手法と範囲

• 調査手法
• 調査の仮定
• 情報調達
  • 購入したデータベース
  • GVRの内部データベース
  • 二次情報
  • 1次調査
  • 1次調査内容
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析
    • アプローチ1：コモディティフローアプローチ
  • ボリューム価格分析（モデル2）
    • アプローチ2：出来高分析
    • 収益モデリング
• 二次情報一覧
• 一次情報のリスト

第2章 オメガ3処方薬市場：エグゼクティブサマリー

• 市場概要

第3章 オメガ3処方薬市場：業界の見通し

• 市場系列の見通し
  • 親市場の見通し
• 浸透と成長の見通しのマッピング
• 市場力学
  • 市場促進要因分析
    • 心血管疾患、肥満、高トリグリセリド血症の有病率の増加
    • 関連する病態を治療するための新規治療薬の開発
    • 免疫サプリメントに関する懸念の高まり
    • 座りっぱなしの生活、在宅勤務の傾向、運動不足
  • 市場制約分析
    • オメガ3処方薬に伴う高コスト
• ポーターのファイブフォース分析
• 要因別SWOT分析（政治と法律、経済、技術）
• 規制の枠組み
• ユーザー視点分析

第4章 オメガ3処方薬市場：競合情勢

• 主要な市場参加者別最近の動向と影響分析
  • Ansoff Matrix
• Major deals &strategic alliances analysis
  • 合弁事業
  • ライセンシングとパートナーシップ
  • 技術協力
• 会社/競合の分類
• ベンダー情勢
  • 主要なディストリビューターとチャネルパートナーのリスト
  • 主要顧客
• 公開会社
  • 会社の市況分析
• プライベートカンパニー
  • 主要な新興企業のリスト
  • 地域ネットワークマップ

第5章 オメガ3処方薬市場：医薬品ビジネス分析

• 定義と範囲
• タイプ市場シェア分析、2021年および2030年
• 世界のオメガ3処方薬市場、医薬品別、2018年から2030年
• 市場規模と予測、トレンド分析、2018年から2030年
  • ヴァセパ
  • ロヴァザ
  • その他

第6章 オメガ3処方薬市場：アプリケーションビジネス分析

• 定義と範囲
• アプリケーション市場シェア分析、2021年および2030年
• 世界のオメガ3処方薬市場、アプリケーション別、2018年から2030年
• 市場規模と予測、トレンド分析、2018年から2030年
  • 高トリグリセリド血症
  • その他

第7章 オメガ3処方薬市場：流通チャネルのビジネス分析

• 定義と範囲
• アプリケーション市場シェア分析、2021年および2030年
• 世界のオメガ3処方薬市場、流通チャネル別、2018年から2030年
• 市場規模と予測、トレンド分析、2018年から2030年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 オメガ3処方薬市場：地域ビジネス分析

• 定義と範囲
• 地域市場シェア分析、2021年および2030年
• 地域市場ダッシュボード
• 地域市場のスナップショット
• SWOT分析、要因別（政治と法律、経済と技術）
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • MEA
• 市場規模、予測、トレンド分析、2021年から2030年
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• MEA
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第9章 オメガ3処方薬市場：企業プロファイリング

• 企業プロファイル
  • Abbott
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Amarin Pharmaceuticals Ireland Limited
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • GSK plc（GlaxoSmithKline Plc）
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Natrapharm, Inc.（Patriot Pharmaceutical Corp.）
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Viatris Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Grupo Ferrer Internacional, SA
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Camber Pharmaceuticals, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Dr. Reddy's Laboratories Ltd.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Zydus Group
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Hikma Pharmaceuticals PLC
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Regulatory Framework
• Table 4 Global Omega 3 Prescription Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 5 Global Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 6 Global Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 7 Global Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 8 North America Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 9 North America Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 10 North America Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 11 North America Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 12 U.S. Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 13 U.S. Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 14 U.S. Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 15 Canada Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 16 Canada Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 17 Canada Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 18 Europe Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 19 Europe Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 20 Europe Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 21 Europe Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 22 U.K. Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 23 U.K. Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 24 U.K. Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 25 Germany Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 26 Germany Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 27 Germany America Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 France Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 29 France Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 30 France Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 31 Spain Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 32 Spain Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 33 Spain Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 Italy Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 35 Italy Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 36 Italy Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 37 Asia Pacific Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 38 Asia Pacific Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 39 Asia Pacific Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 41 China Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 42 China Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 43 China Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 Japan Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 45 Japan Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 46 Japan Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 47 India Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 48 India Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 49 India Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 50 South Korea Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 51 South Korea Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 52 South Korea Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 53 Australia Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 54 Australia Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 55 Australia Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 56 Latin America Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 57 Latin America Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 58 Latin America Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 59 Latin America Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 60 Brazil Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 61 Brazil Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 62 Brazil Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Mexico Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 64 Mexico Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 65 Mexico Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 66 Argentina Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 67 Argentina Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 68 Argentina Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 69 MEA Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 70 MEA Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 71 MEA Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 72 MEA Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 73 South Africa Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 74 South Africa Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 75 South Africa Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 76 Saudi Arabia Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 77 Saudi Arabia Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 78 Saudi Arabia Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 UAE Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 80 UAE Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 81 UAE Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Omega 3 Prescription Drugs Market Segmentation
• Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 11 Penetration & Growth Prospect Mapping
• Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 13 Porter's Five Forces Analysis
• Fig. 14 Market Penetration & Growth Prospect Mapping
• Fig. 15 Omega 3 Prescription Drugs Market: Drug Movement Analysis
• Fig. 16 Vascepa market, 2018 - 2030 (USD Million)
• Fig. 17 Lovaza market, 2018 - 2030 (USD Million)
• Fig. 18 Others market, 2018 - 2030 (USD Million)
• Fig. 19 Omega 3 Prescription Drugs Market: Application Movement Analysis
• Fig. 20 Hypertriglyceridemia market, 2018 - 2030 (USD Million)
• Fig. 21 Others market, 2018 - 2030 (USD Million)
• Fig. 22 Omega 3 Prescription Drugs Market: Distribution Channel Movement Analysis
• Fig. 23 Hospital Pharmacy market, 2018 - 2030 (USD Million)
• Fig. 24 Retail Pharmacy market, 2018 - 2030 (USD Million)
• Fig. 25 Online Pharmacy market, 2018 - 2030 (USD Million)
• Fig. 26 Regional Marketplace: Key Takeaways
• Fig. 27 Regional Outlook, 2018 & 2030
• Fig. 28 Regional Market Dashboard
• Fig. 29 Regional Market Place: Key Takeaways
• Fig. 30 North America, SWOT Analysis
• Fig. 31 Europe, SWOT Analysis
• Fig. 32 Asia Pacific, SWOT Analysis
• Fig. 33 Latin America, SWOT Analysis
• Fig. 34 MEA, SWOT Analysis
• Fig. 35 North America
• Fig. 36 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 37 U.S.
• Fig. 38 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 39 Canada
• Fig. 40 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 41 Europe
• Fig. 42 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 43 U.K.
• Fig. 44 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 45 Germany
• Fig. 46 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 47 France
• Fig. 48 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 49 Italy
• Fig. 50 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 51 Spain
• Fig. 52 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 53 Asia Pacific
• Fig. 54 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 55 Japan
• Fig. 56 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 57 China
• Fig. 58 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 59 India
• Fig. 60 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 61 Australia
• Fig. 62 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 63 South Korea
• Fig. 64 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 65 Latin America
• Fig. 66 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 67 Brazil
• Fig. 68 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 69 Mexico
• Fig. 70 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 71 Argentina
• Fig. 72 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 73 MEA
• Fig. 74 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 75 South Africa
• Fig. 76 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 77 Saudi Arabia
• Fig. 78 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 79 UAE
• Fig. 80 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 81 Strategy Mapping

Omega 3 Prescription Drugs Market Growth & Trends:

The global omega 3 prescription drugs market size is expected to reach USD 2.52 billion by 2030, registering a CAGR of 8.27% over the forecast period, according to a new report by Grand View Research, Inc. The growth of the industry is attributed to the rising cases of Cardiovascular Diseases (CVDs) and altered dietary practices. An elevated level of triglycerides in the blood is now known to be associated with an increased risk of cardiovascular disease. According to the European Society of Cardiology in 2021, 17.9 million people die from CVDs each year, making it the leading cause of death worldwide. Furthermore, due to the expanding product application potential in medicines, omega 3-based pharmaceutical product launches by industry participants are anticipated to boost its growth.

For instance, in 2020, the U.S. FDA authorized a new cardiovascular indication and label expansion for the omega-3 medication VASCEPA, manufactured by U.S.-based Amarin Corporation. An increase in triglycerides can cause artery narrowing, which raises the risk of heart attack and stroke. Pancreatitis, an inflammation of the pancreas, can result from extremely high levels as well. Triglyceride levels rise as a result of diabetes and obesity, which is a widespread issue. An average of 25% of American adults have high borderline blood alcohol concentrations. The omega-3 fatty acid medications are prescribed only for triglycerides levels above 500 mg/dl as approved by the U.S. FDA. The omega 3 prescription drugs demonstrated a significant market movement during the COVID-19 pandemic.

This is owing to their significant role in the management of CVD patients. For instance, in August 2021, Woodward Pharma Services LLC announced the acquisition of LOVAZA from GlaxoSmithKline. The company further aims to educate consumers and providers to facilitate higher adoption of the product. Moreover, multiple R&D studies are being conducted for lowering triglycerides; combined and analyzed findings from 17 organized and randomized clinical trials on elevated triglyceride levels, suggest that prescription omega-3 fatty acid medication can reduce levels by 20-30%. This is expected to create high product demand.

Omega 3 Prescription Drugs Market Report Highlights:

• The vascepa drug segment accounted for the largest revenue share in 2021 as vascepa is approved by the FDA for use in patients for reducing the risk of CVD

• By application, the hypertriglyceridemia segment is expected to register the fastest growth rate over the forecast period

• The growth can be attributed to the increasing use of omega 3 prescription medications for patients with elevated triglyceride levels

• North America dominated the global industry in 2021 owing to the high prevalence of target diseases, with CVD being the leading cause of death in the region

• Key players are focusing on developing advanced and novel dosage forms from existing drugs to meet the rising demand and provide efficient treatment options

Table of Contents

Chapter 1 Omega 3 Prescription Drugs Market: Methodology and Scope

• 1.1 Research Methodology
• 1.2 Research Assumptions
  • 1.2.1 Estimates and forecast timeline
• 1.3 Information Procurement
  • 1.3.1 Purchased database
  • 1.3.2 GVR's internal database
  • 1.3.3 Secondary sources
  • 1.3.4 Primary research
  • 1.3.5 Details of primary research
• 1.4 Information or Data Analysis
  • 1.4.1 Data analysis models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity flow analysis
    • 1.6.1.1 Approach 1: Commodity flow approach
  • 1.6.2 Volume price analysis (model 2)
    • 1.6.2.1 Approach 2: Volume price analysis
    • 1.6.2.2 Revenue modeling
• 1.7 List of Secondary Sources
• 1.8 List of Primary Sources

Chapter 2 Omega 3 Prescription Drugs Market: Executive Summary

• 2.1 Market summary

Chapter 3 Omega 3 Prescription Drugs Market: Industry Outlook

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 Penetration & Growth Prospect Mapping
• 3.3 Market Dynamics
  • 3.3.1 Market Driver Analysis
    • 3.3.1.1 Increasing prevalence of cardiovascular diseases, obesity and hypertriglyceridemia
    • 3.3.1.2 Development of novel drugs for treatment of related disease condition
    • 3.3.1.3 Rising concerns related to immunity supplements
    • 3.3.1.4 Sedentary lifestyles, the trend toward working from home, and a lack of physical activity
  • 3.3.2 Market Restraint Analysis
    • 3.3.2.1 High cost associated with omega 3 prescription drugs
• 3.4 Porter's Five Forces Analysis
• 3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
• 3.6 Regulatory Framework
• 3.7 User Perspective Analysis

Chapter 4 Omega 3 Prescription Drugs Market: Competitive Landscape

• 4.1 Recent developments & impact analysis, by key market participants
  • 4.1.1 Ansoff Matrix
• 4.2 Major deals & strategic alliances analysis
  • 4.2.1 Joint Ventures
  • 4.2.2 Licensing and Partnerships
  • 4.2.3 Technological Collaborations
• 4.3 Company/Competition Categorization
• 4.4 Vendor Landscape
  • 4.4.1 List Of Key Distributors and Channel Partners
  • 4.4.2 Key Customers
• 4.5 Public Companies
  • 4.5.1 Company Market Position Analysis
• 4.6 Private Companies
  • 4.6.1 List Of Key Emerging Companies
  • 4.6.2 Regional Network Map

Chapter 5 Omega 3 Prescription Drugs Market: Drug Business Analysis

• 5.1 Definition and Scope
• 5.2 Type Market Share Analysis, 2021 & 2030
• 5.3 Global Omega 3 Prescription Drugs Market, By Drugs, 2018 to 2030
• 5.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 5.4.1 Vascepa
    • 5.4.1.1 Vascepa Market 2018 - 2030 (USD Million)
  • 5.4.2 Lovaza
    • 5.4.2.1 Lovaza Market, 2018 - 2030 (USD Million)
  • 5.4.3 Others
    • 5.4.2.3 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Omega 3 Prescription Drugs Market: Application Business Analysis

• 6.1 Definition and Scope
• 6.2 Application Market Share Analysis, 2021 & 2030
• 6.3 Global Omega 3 Prescription Drugs Market, By Application, 2018 to 2030
• 6.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 6.4.1 Hypertriglyceridemia
    • 6.4.1.1 Hypertriglyceridemia Market 2018 - 2030 (USD Million)
  • 6.4.2 Others
    • 6.4.2.1 Others Market, 2018 - 2030 (USD Million)

Chapter 7 Omega 3 Prescription Drugs Market: Distribution Channel Business Analysis

• 7.1 Definition and Scope
• 7.2 Application Market Share Analysis, 2021 & 2030
• 7.3 Global Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 to 2030
• 7.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 7.4.1 Hospital Pharmacy
    • 7.4.1.1 Hospital Pharmacy Market 2018 - 2030 (USD Million)
  • 7.4.2 Retail Pharmacy
    • 7.4.2.1 Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 7.4.2 Online Pharmacy
    • 7.4.2.1 Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 8 Omega 3 Prescription Drugs Market: Regional Business Analysis

• 8.1 Definition & Scope
• 8.2 Regional Market Share Analysis, 2021 & 2030
• 8.3 Regional Market Dashboard
• 8.4 Regional Market Snapshot
• 8.5 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • 8.5.1 North America
  • 8.5.2 Europe
  • 8.5.3 Asia Pacific
  • 8.5.4 Latin America
  • 8.5.5 MEA
• 8.6 Market Size, & Forecasts, Trend Analysis, 2021 to 2030
• 8.7 North America
  • 8.7.1 North America Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.7.2 U.S.
    • 8.7.2.1 U.S. Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.7.3 Canada
    • 8.7.3.1 Canada Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
• 8.8 Europe
  • 8.8.1 Europe Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.8.2 U.K.
    • 8.8.2.1 U.K. Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.8.3 Germany
    • 8.8.3.1 Germany Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.8.4 France
    • 8.8.4.1 France Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.8.5 Italy
    • 8.8.5.1 Italy Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.8.6 Spain
    • 8.8.6.1 Spain Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
• 8.9 Asia Pacific
  • 8.9.1 Asia-Pacific Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.9.2 Japan
    • 8.9.2.1 Japan Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.9.3 China
    • 8.9.3.1 China Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.9.4 India
    • 8.9.4.1 India Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.9.5 Australia
    • 8.9.5.1 Australia Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.9.6 South Korea
    • 8.9.6.1 South Korea Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
• 8.10 Latin America
  • 8.10.1 Latin America Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.10.2 Brazil
    • 8.10.2.1 Brazil Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.10.3 Mexico
    • 8.10.3.1 Mexico Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.10.4 Argentina
    • 8.10.4.1 Argentina Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
• 8.11 MEA
  • 8.11.1 MEA Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.11.2 South Africa
    • 8.11.2.1 South Africa Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.11.3 Saudi Arabia
    • 8.11.3.1 Saudi Arabia Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.11.4 UAE
    • 8.11.4.1 UAE Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)

Chapter 9 Omega 3 Prescription Drugs Market: Company Profiling

• 9.1 Company Profiles
  • 9.1.1. Abbott
    • 9.1.1.1 Company overview
    • 9.1.1.2 Financial performance
    • 9.1.1.3 Product benchmarking
    • 9.1.1.4 Strategic Initiatives
  • 9.1.2. Amarin Pharmaceuticals Ireland Limited
    • 9.1.2.1 Company overview
    • 9.1.2.2 Financial performance
    • 9.1.2.3 Product benchmarking
    • 9.1.2.4 Strategic Initiatives
  • 9.1.3. GSK plc (GlaxoSmithKline Plc)
    • 9.1.3.1 Company overview
    • 9.1.3.2 Financial performance
    • 9.1.3.3 Product benchmarking
    • 9.1.3.4 Strategic Initiatives
  • 9.1.4. Natrapharm, Inc. (Patriot Pharmaceutical Corp.)
    • 9.1.4.1 Company overview
    • 9.1.4.2 Financial performance
    • 9.1.4.3 Product benchmarking
    • 9.1.4.4 Strategic Initiatives
  • 9.1.5. Viatris Inc.
    • 9.1.5.1 Company overview
    • 9.1.5.2 Financial performance
    • 9.1.5.3 Product benchmarking
    • 9.1.5.4 Strategic Initiatives
  • 9.1.6. Grupo Ferrer Internacional, S.A.
    • 9.1.6.1 Company overview
    • 9.1.6.2 Financial performance
    • 9.1.6.3 Product benchmarking
    • 9.1.6.4 Strategic Initiatives
  • 9.1.7. Camber Pharmaceuticals, Inc.
    • 9.1.7.1 Company overview
    • 9.1.7.2 Financial performance
    • 9.1.7.3 Product benchmarking
    • 9.1.7.4 Strategic Initiatives
  • 9.1.8 Dr. Reddy's Laboratories Ltd.
    • 9.1.8.1 Company overview
    • 9.1.8.2 Financial performance
    • 9.1.8.3 Product benchmarking
    • 9.1.8.4 Strategic Initiatives
  • 9.1.9 Zydus Group
    • 9.1.9.1 Company overview
    • 9.1.9.2 Financial performance
    • 9.1.9.3 Product benchmarking
    • 9.1.9.4 Strategic Initiatives
  • 9.1.10 Hikma Pharmaceuticals PLC
    • 9.1.10.1 Company overview
    • 9.1.10.2 Financial performance
    • 9.1.10.3 Product benchmarking
    • 9.1.10.4 Strategic Initiatives